About Catabasis Pharmaceuticals
Catabasis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics based on its Safely Metabolized And Rationally Targeted (SMART), a linker drug discovery platform. The SMART linker drug discovery platform enables to engineer product candidates that can modulate multiple targets in a disease. The Company's primary focus is on treatments for rare diseases. The Company is also developing other product candidates for the treatment of lipid disorders. The Company's CAT-1004 is a SMART linker conjugate of salicylate, a non-steroidal anti-inflammatory drug, and the omega-3 fatty acid docosahexaenoic acid (DHA), a naturally occurring unsaturated fatty acid with anti-inflammatory properties. Its CAT-2000 series product candidates inhibit the Sterol Regulatory Element Binding Protein (SREBP) pathway. The Company's CAT-4001 is a SMART linker conjugate of monomethyl fumarate and DHA.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: N/A
- Exchange: NASDAQ
- Symbol: CATB
- Previous Close: $1.19
- 50 Day Moving Average: $2.76
- 200 Day Moving Average: $3.94
- 52-Week Range: $18,652,000.00 - $1.08
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -0.59
- P/E Growth: 0.00
- Market Cap: $22.76M
- Outstanding Shares: 18,652,000
- Beta: 2.39
- Return on Equity: -91.15%
- Return on Assets: -69.61%
Companies Related to Catabasis Pharmaceuticals:
- Debt-to-Equity Ratio: 0.09%
- Current Ratio: 5.65%
- Quick Ratio: 5.65%
What is Catabasis Pharmaceuticals' stock symbol?
Catabasis Pharmaceuticals trades on the NASDAQ under the ticker symbol "CATB."
Where is Catabasis Pharmaceuticals' stock going? Where will Catabasis Pharmaceuticals' stock price be in 2017?
5 equities research analysts have issued 12-month price objectives for Catabasis Pharmaceuticals' stock. Their forecasts range from $4.00 to $16.00. On average, they expect Catabasis Pharmaceuticals' stock price to reach $9.80 in the next twelve months.
When will Catabasis Pharmaceuticals announce their earnings?
Catabasis Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, February, 28th 2017.
Who owns Catabasis Pharmaceuticals stock?
Catabasis Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional investors include SV Life Sciences Advisers LLC (15.32%), FMR LLC (7.38%), Deerfield Management Co. (3.66%), Alyeska Investment Group L.P. (1.20%), Federated Investors Inc. PA (0.86%) and Fred Alger Management Inc. (0.24%). Company insiders that own Catabasis Pharmaceuticals stock include Medimmune Ventures, Inc and Nicholas Galakatos.
Who sold Catabasis Pharmaceuticals stock? Who is selling Catabasis Pharmaceuticals stock?
Catabasis Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Fred Alger Management Inc., FMR LLC and Deerfield Management Co..
Who bought Catabasis Pharmaceuticals stock? Who is buying Catabasis Pharmaceuticals stock?
Catabasis Pharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including Federated Investors Inc. PA and Alyeska Investment Group L.P.. Company insiders that have bought Catabasis Pharmaceuticals stock in the last two years include Medimmune Ventures, Inc and Nicholas Galakatos.
How do I buy Catabasis Pharmaceuticals stock?
Shares of Catabasis Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Catabasis Pharmaceuticals stock cost?
One share of Catabasis Pharmaceuticals stock can currently be purchased for approximately $1.22.